Compare · MDT vs NRXS
MDT vs NRXS
Side-by-side comparison of Medtronic plc. (MDT) and Neuraxis Inc. (NRXS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDT and NRXS operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- MDT is the larger of the two at $105.25B, about 1249.8x NRXS ($84.2M).
- Over the past year, MDT is down 6.8% and NRXS is up 175.9% - NRXS leads by 182.7 points.
- MDT has hit the wire 22 times in the past 4 weeks while NRXS has been quiet.
- MDT has more recent analyst coverage (25 ratings vs 0 for NRXS).
- Company
- Medtronic plc.
- Neuraxis Inc.
- Price
- $82.00+1.66%
- $6.76+1.35%
- Market cap
- $105.25B
- $84.2M
- 1M return
- +7.72%
- -18.36%
- 1Y return
- -6.80%
- +175.92%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NYSE
- AMEX
- IPO
- 2023
- News (4w)
- 22
- 0
- Recent ratings
- 25
- 0
Medtronic plc.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Latest MDT
- EVP & President Cardiovascular Kiil Harry Skip sold $336,965 worth of Ordinary Shares (4,189 units at $80.44), decreasing direct ownership by 10% to 37,227 units (SEC Form 4)
- EVP & President Cardiovascular Kiil Harry Skip covered exercise/tax liability with 6,817 units of Ordinary Shares, decreasing direct ownership by 14% to 41,416 units (SEC Form 4)
- Chairman and CEO Martha Geoffrey covered exercise/tax liability with 41,936 units of Ordinary Shares, decreasing direct ownership by 12% to 301,163 units (SEC Form 4)
- EVP, Pres MedSurg and Americas Marinaro Michael covered exercise/tax liability with 7,471 units of Ordinary Shares, decreasing direct ownership by 11% to 63,122 units (SEC Form 4)
- SVP, Chief HR Officer Walter Matthew R. covered exercise/tax liability with 2,840 units of Ordinary Shares, decreasing direct ownership by 7% to 38,689 units (SEC Form 4)
- Chief Accounting Officer Blomquist Denise L. covered exercise/tax liability with 237 units of Ordinary Shares, decreasing direct ownership by 2% to 14,737 units (SEC Form 4)
- Medtronic upgraded by BTIG Research with a new price target
- Medtronic submits 510(k) filings to expand Hugo™ robotic-assisted surgery system into general and gynecologic specialties in the United States
- Medtronic announces strategic investments to support future expansion of cardiac ablation portfolio as physician demand for Affera™ technologies broadens
- Medtronic plc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest NRXS
- NeurAxis Reports Record First Quarter 2026 Financial Results Driven by 80% Year Over Year Revenue Growth
- SEC Form 10-Q filed by Neuraxis Inc.
- NeurAxis to Host First Quarter 2026 Results and Business Update Call on Tuesday, May 12, 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by Neuraxis Inc.
- Director Aharon Gil was granted 234,221 shares, increasing direct ownership by 57% to 33,902 units (SEC Form 4)
- SEC Form DEFA14A filed by Neuraxis Inc.
- SEC Form DEF 14A filed by Neuraxis Inc.
- Neuraxis Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- NeurAxis Expands Payer Coverage with Four New Medical Policies
- Neuraxis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition